David Chang
2020
In 2020, David Chang earned a total compensation of $7.8M as President and Chief Executive Officer at Allogene Therapeutics, a 30% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $506,250 |
|---|---|
| Option Awards | $6,550,535 |
| Salary | $675,000 |
| Other | $83,256 |
| Total | $7,815,041 |
Chang received $6.6M in option awards, accounting for 84% of the total pay in 2020.
Chang also received $506.3K in non-equity incentive plan, $675K in salary and $83.3K in other compensation.
Rankings
In 2020, David Chang's compensation ranked 1,199th out of 13,090 executives tracked by ExecPay. In other words, Chang earned more than 90.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,199 out of 13,090 | 91st |
Division Manufacturing | 424 out of 5,620 | 93rd |
Major group Chemicals And Allied Products | 146 out of 2,253 | 94th |
Industry group Drugs | 126 out of 1,953 | 94th |
Industry Biological Products, Except Diagnostic Substances | 33 out of 411 | 92nd |
Source: SEC filing on April 22, 2021.
Chang's colleagues
We found four more compensation records of executives who worked with David Chang at Allogene Therapeutics in 2020.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019